Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.31 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14321915 | 0.86 | BCHE (0.33) | BCHEGAAANO1P2RX4 | |
| SCHEMBL2369513 | 0.78 | PARP1 (0.36) | — | |
| SCHEMBL14321964 | 0.70 | ALDH1A1 (0.32) | CNR1 | |
| SCHEMBL30923855 | 0.68 | BUB1 (0.36) | BCHEMEN1NPC1RAB9AKMT2A | |
| SCHEMBL30923857 | 0.68 | BUB1 (0.36) | BCHEMEN1NPC1RAB9AKMT2A | |
| SCHEMBL19278216 | 0.67 | ABL1 (0.36) | GAA | |
| SCHEMBL16475117 | 0.66 | ALDH1A1 (0.35) | — | |
| SCHEMBL23291994 | 0.64 | GABRG2 (0.39) | BCHE | |
| SCHEMBL12033243 | 0.63 | BUB1 (0.35) | BCHE | |
| SCHEMBL14321692 | 0.62 | ALDH1A1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120329826-A1 | SUBSTITUTED-5-AMINOPYRROLO/PYRAZOLOPYRIDINES | OSI Pharmaceuticals,. LLC | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329826-A1 | SUBSTITUTED-5-AMINOPYRROLO/PYRAZOLOPYRIDINES | MET, KRAS, VHL | BCHE 4322/4885GAA 2465/4885ANO1 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.